The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.
Song MJ, Pan QZ, Ding Y, Zeng J, Dong P, Zhao JJ, Tang Y, Li J, Zhang Z, He J, Yang J, Huang Y, Peng R, Wang QJ, Gu JM, He J, Li YQ, Chen SP, Huang R, Zhou ZQ, Yang C, Han Y, Chen H, Liu H, Xia S, Wan Y, Weng DS, Xia L, Zhou FJ, Xia JC.
Song MJ, et al. Among authors: han y.
Clin Transl Immunology. 2021 Mar 3;10(3):e1257. doi: 10.1002/cti2.1257. eCollection 2021.
Clin Transl Immunology. 2021.
PMID: 33717483
Free PMC article.